Nonselective inhibition of cyclooxygenase (COX) by nonsteroidal anti- inflam matory drugs frequently induces renal failure in decompensated cirrhosis. Studie s in experimental cirrhosis suggest that selective inhibito...Nonselective inhibition of cyclooxygenase (COX) by nonsteroidal anti- inflam matory drugs frequently induces renal failure in decompensated cirrhosis. Studie s in experimental cirrhosis suggest that selective inhibitors of the inducible i soform COX- 2 do not adversely affect renal function. However, very limited inf ormation is available on the effects of these compounds on renal function in hum an cirrhosis. This investigation consists of a double- blind, randomized, place bo- controlled trial aimed at comparing the effects of the selective COX- 2 in hibitor celecoxib (200 mg every 12 hours for a total of 5 doses) on platelet and renal function and the renal response to furosemide (40 mg intravenously) with those of naproxen (500 mg every 12 hours for a total of 5 doses) and placebo in 28 patients with cirrhosis and ascites. A significant reduction (P < 0 .05) in g lomerular filtration rate (113 ± 27 to 84 ± 22 mL/min), renal plasma flow (5 92 ± 158 to 429 ± 106 mL/min) and urinary prostaglandin E2 excretion (3430 ± 430 to 2068 ± 549 pg/min) and suppression of the diuretic (urine volume: 5 61 ± 128 to 414 ± 107 mL/h) and natriuretic (urine sodium: 53 ± 13 to 34 ± 10 mEq/h) responses to furosemide were observed in the group of patients tre ated with naproxen but not in the other two groups. Naproxen, but not celecoxib or placebo, significantly inhibited platelet aggregation (72% ± 8% to 47% ± 8% , P < 0 .05) and thromboxane B2 production (41 ± 12 to 14 ± 5 pg/mL, P< 0.05). In conclusion, our results indicate that short- term administration of celecoxib does not impair platelet and renal function and the response to diu retics in decompensated cirrhosis.展开更多
目的:比较奈普生的口服剂型与直肠栓剂治疗原发性痛经的疗效。方法:选用362例原发性痛经患者随机分组,观察组采用奈普生的直肠栓剂(舒经栓)治疗,对照组采用口服奈普生治疗。结果:奈普生的直肠栓剂使用后10 m in及1 h对痛经的疗效明显优...目的:比较奈普生的口服剂型与直肠栓剂治疗原发性痛经的疗效。方法:选用362例原发性痛经患者随机分组,观察组采用奈普生的直肠栓剂(舒经栓)治疗,对照组采用口服奈普生治疗。结果:奈普生的直肠栓剂使用后10 m in及1 h对痛经的疗效明显优于口服奈普生,同时对痛经所致胃肠道症状的缓解明显优于口服剂型。结论:奈普生的直肠栓剂能快速有效地治疗原发性痛经。展开更多
文摘Nonselective inhibition of cyclooxygenase (COX) by nonsteroidal anti- inflam matory drugs frequently induces renal failure in decompensated cirrhosis. Studie s in experimental cirrhosis suggest that selective inhibitors of the inducible i soform COX- 2 do not adversely affect renal function. However, very limited inf ormation is available on the effects of these compounds on renal function in hum an cirrhosis. This investigation consists of a double- blind, randomized, place bo- controlled trial aimed at comparing the effects of the selective COX- 2 in hibitor celecoxib (200 mg every 12 hours for a total of 5 doses) on platelet and renal function and the renal response to furosemide (40 mg intravenously) with those of naproxen (500 mg every 12 hours for a total of 5 doses) and placebo in 28 patients with cirrhosis and ascites. A significant reduction (P < 0 .05) in g lomerular filtration rate (113 ± 27 to 84 ± 22 mL/min), renal plasma flow (5 92 ± 158 to 429 ± 106 mL/min) and urinary prostaglandin E2 excretion (3430 ± 430 to 2068 ± 549 pg/min) and suppression of the diuretic (urine volume: 5 61 ± 128 to 414 ± 107 mL/h) and natriuretic (urine sodium: 53 ± 13 to 34 ± 10 mEq/h) responses to furosemide were observed in the group of patients tre ated with naproxen but not in the other two groups. Naproxen, but not celecoxib or placebo, significantly inhibited platelet aggregation (72% ± 8% to 47% ± 8% , P < 0 .05) and thromboxane B2 production (41 ± 12 to 14 ± 5 pg/mL, P< 0.05). In conclusion, our results indicate that short- term administration of celecoxib does not impair platelet and renal function and the response to diu retics in decompensated cirrhosis.
文摘目的:比较奈普生的口服剂型与直肠栓剂治疗原发性痛经的疗效。方法:选用362例原发性痛经患者随机分组,观察组采用奈普生的直肠栓剂(舒经栓)治疗,对照组采用口服奈普生治疗。结果:奈普生的直肠栓剂使用后10 m in及1 h对痛经的疗效明显优于口服奈普生,同时对痛经所致胃肠道症状的缓解明显优于口服剂型。结论:奈普生的直肠栓剂能快速有效地治疗原发性痛经。
